- Trials with a EudraCT protocol (44,339)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (18,700)
44,339 result(s) found.
Displaying page 1,068 of 2,217.
EudraCT Number: 2014-004787-37 | Sponsor Protocol Number: VX14-661-107 | Start Date*: 2015-09-21 | |||||||||||
Sponsor Name:Vertex Pharmaceuticals Incorporated | |||||||||||||
Full Title: A Phase 3, Randomized, Double-blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cy... | |||||||||||||
Medical condition: Cystic Fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) DE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004545-27 | Sponsor Protocol Number: GS-US-366-1216 | Start Date*: 2015-06-16 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positiv... | |||||||||||||
Medical condition: Human Immunodeficiency Virus (HIV-1) Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DE (Completed) GB (Completed) BE (Completed) ES (Completed) NL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005882-19 | Sponsor Protocol Number: 109995 | Start Date*: 2015-06-25 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: Non-inferiority of GSK Biologicals’ measles-mumps-rubella-varicella (MMRV) vaccine 208136 vs Priorix™ and Priorix™ coadministered with Varilrix™ (comparator) and to evaluate non-inferiority of Prio... | ||
Medical condition: Measles, mumps, rubella and varicella diseases | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2012-002228-34 | Sponsor Protocol Number: 2012/1vas | Start Date*: 2015-09-30 | |||||||||||||||||||||
Sponsor Name:Diego Caicedo Valdés | |||||||||||||||||||||||
Full Title: Growth hormone (GH) angiogenic effect clinical trial on patients with lower limb critical ischemia. GHAS Study | |||||||||||||||||||||||
Medical condition: Lower limb critical ischemia | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000584-14 | Sponsor Protocol Number: AGLU03807,MSC12862 | Start Date*: 2015-04-15 | |||||||||||
Sponsor Name:Genzyme Corporation Inc | |||||||||||||
Full Title: An Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme-naïve CRIM(-) Patients with Infantile-Onset Pompe Disease | |||||||||||||
Medical condition: Pompe disease (acid alpha-glucosidase deficiency) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004175-23 | Sponsor Protocol Number: A9451165 | Start Date*: 2015-04-07 |
Sponsor Name:Pfizer Japan Inc | ||
Full Title: A 52 weeks, open-label, multicenter study evaluating the efficacy and safety of gabapentin as adjunctive therapy in pediatric subjects who have completed the 12 weeks treatment in study A9451162. | ||
Medical condition: Epilepsy with partial seizures (including secondarily generalized seizures) | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2014-004964-39 | Sponsor Protocol Number: 51503 | Start Date*: 2015-05-22 |
Sponsor Name:Sint Antonius Ziekenhuis | ||
Full Title: Clonidine as Additive for Locoregional Postoperative Analgesia in Foot and Anckle Surgery | ||
Medical condition: Postoperative pain | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-001704-22 | Sponsor Protocol Number: CCD-05993AA1-08 | Start Date*: 2015-02-25 | |||||||||||
Sponsor Name:Chiesi Farmaceutici S.p.A. | |||||||||||||
Full Title: A 52-week, Double Blind, Double dummy, Randomized, Multinational, Multicentre, 2-arm Parallel Group, active Controlled Clinical Trial of fixed combination of beclometasone dipropionate plus formote... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) PT (Completed) HU (Completed) CZ (Completed) RO (Completed) DK (Completed) DE (Completed) AT (Completed) NO (Completed) PL (Completed) FR (Completed) BG (Completed) HR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-005026-35 | Sponsor Protocol Number: 35RC14_9853_DEXA-OP | Start Date*: Information not available in EudraCT | ||||||||||||||||
Sponsor Name:Centre Hospitalier Universitaire de Rennes | ||||||||||||||||||
Full Title: Study DEXA-OP. Can the dexaméthasone replace the kétoprofène in the strategy of per-operating multimodal analgesia in pediatric ambulatory surgery? A double-blind randomized comparative study. | ||||||||||||||||||
Medical condition: Per-operating analgesia, pediatric ambulatory surgery | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001216-35 | Sponsor Protocol Number: CONCERTAATT4086 | Start Date*: 2015-04-24 | |||||||||||
Sponsor Name:Johnson & Johnson Taiwan Ltd | |||||||||||||
Full Title: From Immediate-release MPH to OROS MPH: The Impact Upon Family of Children and Adolescents With ADHD | |||||||||||||
Medical condition: Attention Deficit Hyperactivity Disorder | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002328-34 | Sponsor Protocol Number: KB056 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:KEDRION S.P.A | |||||||||||||
Full Title: Efficacy and safety evaluation of Kedrion Fibrin Sealant as an adjuvant for the control of hemostasis in pediatric patients undergoing abdominal or orthopedic surgery. Multicenter, randomized, cont... | |||||||||||||
Medical condition: Paediatric patients undergoing abdominal or orthopedic surgery | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001218-92 | Sponsor Protocol Number: CON-KOR-012 | Start Date*: 2015-04-24 | |||||||||||
Sponsor Name:Janssen Korea Ltd | |||||||||||||
Full Title: A prospective, open-labeled, multicenter study of optimal dosages of OROS-methylphenidate in treating children and adolescents with Attention-Deficit Hyperactivity Disorder | |||||||||||||
Medical condition: Attention Deficit Hyperactivity Disorder | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-005387-25 | Sponsor Protocol Number: noprofit1616 | Start Date*: 2016-05-05 | |||||||||||
Sponsor Name:Sapienza, University of Rome | |||||||||||||
Full Title: Phase 2a Study of an Immunotherapeutic Vaccine, DPX-Survivac, Alone or with Low dose Cyclophosphamide in Primary Glioblastoma Patients Receiving Standard of Care Therapy | |||||||||||||
Medical condition: Glioblastoma is the most common primary brain tumour in humans with the most severe prognosis. Standard treatments consist primarily of surgery in order to debulk thetumoral mass, as well as radioc... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001076-22 | Sponsor Protocol Number: 03-0-160 | Start Date*: 2015-04-13 | |||||||||||
Sponsor Name:Fujisawa Healthcare, Inc. | |||||||||||||
Full Title: A PHASE II, OPEN-LABEL, MULTI-CENTER STUDY TO ASSESS THE PHARMACOKINETICS, LONG-TERM SAFETY AND TOLERABILITY OF TACROLIMUS IN STABLE PEDIATRIC LIVER TRANSPLANT PATIENTS CONVERTED FROM A PROGRAF® BA... | |||||||||||||
Medical condition: Liver transplant rejection | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001041-83 | Sponsor Protocol Number: FKC-009 | Start Date*: 2015-04-13 | |||||||||||
Sponsor Name:Astellas Pharma Canada Inc. | |||||||||||||
Full Title: Clinical and Laboratory Evaluation of Acute Rejection, Myocyte Growth, Repair, and Oxidative Stress Following de novo Cardiac Transplant: A Comparison between Tacrolimus- and Cyclosporine- based Im... | |||||||||||||
Medical condition: Cardiac transplant recipients | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004464-38 | Sponsor Protocol Number: 20120296 | Start Date*: 2015-06-25 | |||||||||||
Sponsor Name:Amgen Inc | |||||||||||||
Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention | |||||||||||||
Medical condition: Migraine Prevention | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) SE (Completed) CZ (Completed) DE (Completed) SK (Completed) AT (Completed) PL (Completed) HU (Prematurely Ended) BE (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003267-55 | Sponsor Protocol Number: A3L45 | Start Date*: 2015-09-03 | ||||||||||||||||||||||||||
Sponsor Name:Sanofi Pasteur SA | ||||||||||||||||||||||||||||
Full Title: An international, multicenter, open-label, one-arm study in 150 infants vaccinated with a 3-dose primary series of the DTaP-IPV-Hep B-PRP-T combined vaccine in the Russian Federation and Poland. | ||||||||||||||||||||||||||||
Medical condition: Prevention of infections caused by Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, poliovirus type 1, 2 and 3, prevention against invasive infections caused by Haemophilus in... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: PL (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-001696-51 | Sponsor Protocol Number: 25735 | Start Date*: 2015-07-15 |
Sponsor Name:Merck KGaA
[...]
1. Merck KGaA
2. Merck Serono s.a.s. |
||
Full Title: Optimization of the Dosage Regimen With Growth Hormone Therapy in Children Born Small for Gestational Age. An Open Label, Randomized, Pilot Study, Comparing in Children Treated for 3 Years, the Eff... | ||
Medical condition: Small for Gestational Age (SGA) | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2015-002895-26 | Sponsor Protocol Number: PrEP-CS-001 | Start Date*: 2015-09-08 | |||||||||||
Sponsor Name:hVIVO Services Limited | |||||||||||||
Full Title: A Phase II, Repeated Dose, Double-Blinded, Randomised, Controlled Study to Examine the Prophylactic Efficacy, Safety and Tolerability of PrEP-001 in Healthy Subjects Subsequently Challenged with In... | |||||||||||||
Medical condition: Influenza A/Perth/16/2009(H3N2) Virus | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-005635-14 | Sponsor Protocol Number: BUX-3/UCA | Start Date*: 2015-06-08 | |||||||||||
Sponsor Name:Dr. Falk Pharma GmbH | |||||||||||||
Full Title: Open-label, multi-centre, proof of concept phase IIa clinical trial on the efficacy and tolerability of an 8 week oral treatment with once daily 9 mg budesonide in patients with active ulcerative c... | |||||||||||||
Medical condition: Patients with active ulcerative colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) LV (Completed) HU (Completed) LT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
